Results 171 to 180 of about 19,674 (249)

Survodutide for the Treatment of Obesity Disease in Japanese Participants: Rationale, Design and Baseline Characteristics of the Phase 3 SYNCHRONIZE‐JP Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims There is an unmet need for effective pharmacotherapy for obesity disease management in Japan. Survodutide is a novel glucagon receptor/glucagon‐like peptide‐1 receptor (GLP‐1R) dual agonist with the potential to induce greater weight reductions than GLP‐1R mono‐agonists. We report the design and baseline participant characteristics of the
Koutaro Yokote   +10 more
wiley   +1 more source

Insulin Sensitivity and Beta Cell Function With Macupatide Alone or With Dulaglutide in Type 2 Diabetes: A Phase 1b, Randomised Controlled Trial

open access: yesDiabetes, Obesity and Metabolism, EarlyView.
ABSTRACT Aims This Phase 1b, randomised, double‐blind clinical trial investigated the contribution of glucose‐dependent insulinotropic polypeptide (GIP) and glucagon‐like peptide‐1 (GLP‐1) to insulin sensitivity and secretion in people with type 2 diabetes (T2D) on metformin. Materials and Methods Participants were randomised to receive the long‐acting
Tim Heise   +10 more
wiley   +1 more source

Competition and payments to African chiefs on the Gold Coast during the slave trade, 1679‒1704

open access: yesThe Economic History Review, EarlyView.
Abstract The manuscript records of the Royal African Company show that the Company paid African chiefs for access to trade along the caravan routes on the Gold Coast in the seventeenth century. This paper documents and examines these payments. Using an event study, I establish that after the Glorious Revolution in 1688 when the Company's monopoly in ...
Jose Rowell Corpuz
wiley   +1 more source

Determination of the tolerable upper intake level of leucine in acute dietary studies in young men.

open access: yesAmerican Journal of Clinical Nutrition, 2012
R. Elango   +4 more
semanticscholar   +1 more source

Evaluation of the effectiveness and safety of anti‐CGRP monoclonal antibodies in patients with migraine and autoimmune diseases: IMMUNO‐CGRP study

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Objective This study aimed to evaluate demographic characteristics, treatment effectiveness, and safety outcomes in patients with migraine undergoing anti‐calcitonin gene‐related peptide (CGRP) treatments regarding the presence of autoimmune diseases. Background CGRP has an important role in migraine pathophysiology through neuronal modulation
María Clara García‐Castillo   +37 more
wiley   +1 more source

Nutrition Information Briefs - Niacin. [PDF]

open access: yesAdv Nutr
Meyer-Ficca ML, Chini CC.
europepmc   +1 more source

The pharmacology of gepants in migraine: A scoping review on mechanisms, clinical applications, and combination strategies

open access: yesHeadache: The Journal of Head and Face Pain, EarlyView.
Abstract Background Calcitonin gene‐related peptide (CGRP) is a key mediator in migraine pathophysiology, and the development of gepants, novel CGRP receptor antagonists, has expanded therapeutic options for both acute and preventive treatment. This scoping review aims to synthesize current evidence on the pharmacology, clinical applications, safety ...
Luigi Francesco Iannone   +5 more
wiley   +1 more source

Co-occurrence of selenium and toxic elements and health risk assessment in commercial selenium-enriched rice from China. [PDF]

open access: yesSci Rep
Xie Q   +11 more
europepmc   +1 more source

Evolving treatments for Sjögren disease: current approaches and emerging targets

open access: yesInternal Medicine Journal, EarlyView.
Abstract Sjögren disease (SjD) is a prevalent systemic autoimmune condition characterised by exocrine gland dysfunction, systemic inflammation and heterogeneous organ involvement. Current management remains largely symptomatic, with no approved disease‐modifying therapies available and substantial unmet clinical need. However, advances in understanding
Mansi Bhurani   +3 more
wiley   +1 more source

Home - About - Disclaimer - Privacy